© 2000 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Postprandial Hyperlipidemia in Streptozotocin-Induced Diabetic Rats Is Due to Abnormal Increase in Intestinal Acyl Coenzyme A:Cholesterol Acyltransferase Activity
From Pharmaceuticals Research Laboratories, Fujirebio Inc, Hachioji, Tokyo, Japan.
Correspondence to Jun Kusunoki, Pharmaceuticals Research Laboratories, Fujirebio Inc, 51 Komiya-cho, Hachioji, Tokyo 192-0031, Japan.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—Postprandial hyperlipidemia (PH) is recognized as a significant risk factor for cardiovascular disease. The present study, involving rats with streptozotocin (STZ)-induced diabetes, was performed to establish a PH model and to examine the relation between small intestinal acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity and serum lipid levels in the postprandial state. The small intestinal ACAT activities in normal rats during the experimental period were 4 to 5 pmol/mg protein per minute. In contrast, in the diabetic rats, the ACAT activities were 2 to 3 times higher than activities seen in normal rats from 7 to 21 days after the STZ injection in the absence of a high fat diet and hyperplasia in the gut. In an oral fat-loading test that used diabetic rats that had been injected with STZ (60 mg/kg) intravenously 14 days previously, the postloading changes in the serum concentrations of total cholesterol (TC) and triglyceride (TG) were significantly greater in the diabetic rats than in normal rats. Single oral administration of (1s,2s)-2-[3-(2,2-dimethylpropyl)-3-nonylureido]cyclohexane-1-yl 3-[(4R)-N-(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propionate (F-1394, 3 to 30 mg/kg), a potent ACAT inhibitor, suppressed the post–fat-loading elevation of serum TC levels in the diabetic rats in a dose-dependent manner without affecting serum glucose levels. Furthermore, the small intestinal ACAT activity, serum TG levels, and lymphatic absorption of TC and TG in the rats that were administered F-1394 (30 mg/kg) were reduced by
90%, 70%, 30%, and
15%, respectively. This is the first evidence that elevated ACAT
activity in the gut, unlike hyperplasia and hyperphagia, induces PH in
rats. Our results strongly suggest that F-1394 may be a potential
treatment for PH in humans.
Key Words: acyl coenzyme A:cholesterol acyltransferase • streptozotocin-induced diabetic rats • postprandial hyperlipidemia • F-1394 • fat-loading test
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Coronary heart disease (CHD) resulting from premature atherosclerosis is a major cause of death in insulin-dependent and non–insulin-dependent diabetic patients.1 2 Abnormalities in the metabolism of plasma lipoproteins and lipids in the postprandial state have been reported in diabetic patients,3 4 5 6 7 8 9 and now evidence is being accumulated indicating that postprandial increases in triglyceride (TG)-rich lipoprotein,10 11 which is known as one of the atherogenic remnant lipoproteins,12 13 TG,14 15 and cholesterol16 remarkably contribute to the occurrence of CHD in such patients.
A number of studies have reported that rats with streptozotocin (STZ)-induced diabetes (STZ-diabetic rats) shows severe hyperlipidemia after exogenous fat loading.17 18 19 It has been suggested that the severe hyperlipidemia occurring in STZ-diabetic rats fed a high fat diet could be attributable to a marked increase in fat absorption via the gut, which in turn could be due to an abnormal increase in small intestinal acyl- coenzyme A:cholesterol acyltransferase (ACAT) activity.20 Indeed, repeated administration of an ACAT inhibitor, such as DL-melinamide,21 CL-277082,22 23 or FR 145237,24 markedly decreases both the serum total cholesterol (TC) level and enhanced small intestinal ACAT activity in STZ-diabetic rats fed a high fat diet. However, previous investigators using diabetic models have not been able to find a correlation between the postprandial metabolism of serum lipids and severe hyperlipidemia, although postprandial hyperlipidemia (PH) is found in diabetic patients.3 4 5 6 7 8 9
The present study was performed to establish a PH model and to examine the relation between enhanced small intestinal ACAT activity and PH. First, we showed that intestinal ACAT activity was markedly enhanced in STZ-diabetic rats in the absence of both a high fat diet and hyperplasia in the gut. Then we examined the changes in serum lipid levels in the postprandial state in STZ-diabetic rats given a high fat cocktail containing cholesterol and sesame oil by mouth. In addition, we examined the effect of a single administration of (1s,2s)-2-[3-(2,2-dimethylpropyl)-3-nonylureido]cyclohexane-1-yl 3-[(4R)-N-(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propionate (F-1394), a potent ACAT inhibitor,25 26 27 28 on serum lipid levels, lymphatic output of lipids, and small intestinal ACAT activity in STZ-diabetic rats after this oral fat loading.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Drugs and Chemicals
[1-14C]Oleoyl-coenzyme A (2.0 GBq/mmol) was obtained from New England Nuclear Corp. F-1394 (Fujirebio Inc) was used to produce potent ACAT inhibition.25 STZ was purchased from Wako Pure Chemical Industries Ltd. All other reagents used were standard commercial high-purity materials.
Animals
Male Sprague-Dawley (SD) rats (5 weeks old) were obtained from
Charles River Japan (Atsugi, Japan). They were maintained in a
temperature- and humidity-regulated room (22±2°C, 55±15%) with
controlled lighting (12-hour light/dark cycle). They had free access to
tap water and commercial regular chow (F-2, Funabashi Farms) for a week
before receiving an STZ injection and throughout the experiments,
except where otherwise stated. After an overnight fast, rats were
injected with STZ (60 mg/kg) in 50 mmol/L citrate-buffered saline
(pH 4.5) via a tail vein to induce diabetes. Control (nondiabetic) rats
were injected with vehicle (citrate-buffered saline). The
intravenous injections were given under light ether
anesthesia. The rats were maintained for various periods,
depending on the aim of the experiments, and then euthanized under
the anesthesia.
Ex Vivo ACAT Assay
The first 20-cm segment of bowel after the gastric pylorus was
removed and discarded. The next 40-cm segment of small intestine was
quickly excised, and the lumen was washed out with chilled saline. This
segment was opened longitudinally, and the mucosa was scraped off (by
using the edge of a microscope slide) and suspended in an ice-cold 0.25
mol/L sucrose solution. The suspension was centrifuged at
900g for 10 minutes, and the residue was
homogenized in 0.154 mol/L potassium phosphate buffer (pH
6.2). The resulting homogenate was centrifuged at
1000g for 15 minutes, and the supernatant was used for ACAT
assays.
ACAT activity was determined by a method involving the incorporation of [14C]oleoyl-coenzyme A into cholesteryl oleate, as described by Heider et al.29 Except when the ACAT activity was to be determined in the fat-loading test, cholesterol liposomes were exogenously added to the assay system to act as an additional substrate for ACAT and thus to facilitate evaluation of the actual activity of intestinal ACAT. The cholesterol-liposome suspension was prepared as follows. Cholesterol and lecithin dissolved in ethanol were rapidly added to 0.154 mol/L potassium phosphate buffer (pH 7.4). The resulting suspension containing 1.5 mmol/L cholesterol and 9 mmol/L lecithin was dialyzed against a large amount of the same buffer to remove the ethanol and was then used as a cholesterol-liposome suspension.
Oral Fat-Loading Test
Rats that had been maintained for 2 weeks after the injection of
STZ or its vehicle were fasted overnight and then given by mouth 5 mL
high fat cocktail per rat. Blood was collected immediately and at 1, 2,
4, 6, and 8 hours after the oral administration of the cocktail. In
each case, blood was collected with the rats under ether
anesthesia. The cocktail, which contained 10% (wt/vol)
cholesterol, 2% (wt/vol) cholic acid, 25% (wt/vol) sesame
oil, 6% (vol/vol) Tween 20, and 0.5% (wt/vol) carboxymethylcellulose
sodium (CMC-Na), was prepared by homogenization
with a Polytron homogenizer (Kinematica GmbH). F-1394
(3 to 30 mg · 5 mL-1 ·
kg-1) or its vehicle (0.5% CMC-Na solution) was
orally administered to rats immediately before they received the
cocktail, and blood was collected 4 hours after administration of the
cocktail.
Lymphatic Output of Lipids
Two weeks after the injection of STZ (60 mg/kg IV), the rats
were fasted overnight and then were orally given 2.5 mL of saline 1
hour before lymphatic cannulation to visualize a lymph duct. The rats
were then anesthetized with sodium pentobarbital (50 mg
· mL-1 · kg-1 IP
Nembutal, Dainippon Pharmaceuticals) and subjected to cannulation of
the thoracic duct as previously described.30 31 32 A second
indwelling catheter was placed in the fore stomach for later
administration of the high fat cocktail and/or F-1394. After the
surgery, the rats were placed in cages to recover from
anesthesia. Each rat was given 3 mL of the cocktail through
a gastric tube, and the lymph was collected every 1 hour, starting at 1
hour before the administration of the cocktail to 24 hours after. Also,
F-1394 (30 mg · 5 mL-1 ·
kg-1) or its vehicle (0.5% CMC-Na solution) was
given via the gastric tube immediately before the administration of the
cocktail. The concentrations of TC and TG in the lymph were determined
enzymatically as mentioned above.
Lipoprotein Subfractionation and Measurement of Biochemical
Parameters
The concentrations of TC, TG, and glucose in a sample were
measured by enzymatic/colorimetric methods with
commercial assay kits (Cholesterol E-HA Test Wako,
Triglyceride EII-HA Test Wako, and Glucose II-HA Test Wako,
respectively; Wako Pure Chemical Industries). Lipoproteins were
isolated by ultracentrifugation, as previously
described.33 The following density (d) fractions were
obtained: d<1.006 g/mL for chylomicrons (CMs)+VLDL, 1.006<d<1.063
for LDL, and 1.063<d<1.210 g/mL for HDL. The concentration of TC in
each fraction was determined enzymatically by using the assay kit
described above.
Statistical Analysis
The results are expressed as mean±SE. The statistical
significance of the differences between groups was determined by means
of a Student t test or Aspin-Welch test, and the differences
among group in the dose-related experiment were determined by means of
a Dunnet, Williams, or Steel test.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Establishment of PH Model in Diabetic Rats
On day 0 (the day of STZ injection), the serum glucose level in the control rats was almost the same as that in the rats injected with STZ. However, the glucose level in the (diabetic) rats injected with STZ was
400 mg/dL at 
3 days, whereas in the control (nondiabetic)
rats, it remained at <200 mg/dL (Table 1
). It was confirmed that diabetes was
obviously induced in rats by STZ injection.
|
In terms of the serum TC and TG levels, there were no significant
differences between the nondiabetic and the diabetic rats throughout
the experimental period. However, on the 21st day, slight
nonsignificant increases in serum TC and TG levels were observed in the
diabetic rats (Table 1
). Although, in this experiment, the food
consumption of regular chow diet was controlled (30 g/d per rat) in
both groups to exclude the influence of overeating, nondiabetic rats
showed increases in body weight and small intestine weight of 30% and
16%, respectively, whereas the diabetic rats showed little or no
change in these parameters throughout the experimental
period (Table 1).
The small intestinal ACAT activity in the nondiabetic rats during the
experimental period was 4 to 5 pmol · mg
protein-1 · min-1.
In contrast, in the diabetic rats, the ACAT activity had reached
11.0±0.7 pmol · mg protein-1 ·
min-1 at 14 days after the injection and then
decreased to 7.4±0.4 pmol · mg
protein-1 · min-1
at 21 days after the injection (Figure 1). Therefore, the rats that had received
STZ 14 days in advance were used for fat-loading experiments.
|
). The rats had free access to tap water, but the daily
food ration was controlled (30 g per rat) to ensure equal intake in the
2 groups. ACAT activity was determined after the incorporation of
[14C]oleoyl-coenzyme A into the cholesteryl oleate
present in a mixture containing a homogenate of small
intestinal mucosa and cholesterol liposome (an additional
substrate for ACAT). Each symbol represents mean±SE from 3
rats. 
P<0.01 and §P<0.001 vs vehicle
group (Student t test).
The values obtained for the initial concentrations of serum TC in
nondiabetic rats and diabetic rats were 71±3 and 58±7 mg/dL,
respectively. In the diabetic rats, the TC level increased rapidly
after the oral administration of a high fat cocktail
(cholesterol, 0.5 g per rat; sesame oil, 1.25 g
per rat); the TC level was 99±8 mg/dL 4 hours after the administration
of the cocktail (P<0.05 versus the nondiabetic rats), and
it reached 110±9 mg/dL after 8 hours. In contrast, the TC level in the
nondiabetic rats rose more slowly; it reached 77±3 mg/dL 4 hours after
the administration of the cocktail and 97±4 mg/dL after 8 hours
(Figure 2A). However, the postprandial
changes in serum TG were much more drastic than changes in serum TC in
the diabetic rats. The values obtained for initial concentrations of TG
in the nondiabetic rats and the diabetic rats were 63±4 and 40±6
mg/dL, respectively. The highest level of serum TG in nondiabetic rats
was only 167±17 mg/dL (2 hours after the oral administration of the
cocktail); thereafter, the level gradually declined to 145±31 mg/dL.
In the diabetic rats, the TG level was dramatically increased to
920±282 mg/dL 4 hours after the administration of the cocktail
(P<0.05 versus nondiabetic rats), and it then declined to
503±87 mg/dL after 8 hours (P<0.01 versus nondiabetic
rats) (Figure 2B). Therefore, the time point at 4 hours after
the administration of the cocktail was selected to evaluate the effect
of an ACAT inhibitor, F-1394, on PH in this model.
|
Effect of F-1394 on PH in Diabetic Rats
As shown in Table 2, the serum
glucose level in the diabetic rats (163±14 mg/dL) was 1.6 times higher
than that in the nondiabetic rats (P<0.01). F-1394 (3 to 30
mg/kg) did not affect the serum glucose levels in the diabetic rats
(Table 2, Figure 3A).
|
|
As shown in Table 2, the serum TC level was significantly higher
in the diabetic control rats than that in the nondiabetic rats
(P<0.05). Also, as shown in Figure 3B, the serum TC
levels reached 115±6 mg/dL 4 hours after the administration of the
cocktail in the diabetic control rats. F-1394 (3, 10, or 30 mg/kg PO)
reduced the serum TC level in the diabetic rats in a dose-dependent
manner (Figure 3B). F-1394 at a dose of 30 mg/kg significantly
reduced the serum TC levels to normal (P<0.001; Table 2, Figure 3B). In fact, it was reduced 25%. An analysis
of lipoprotein subfractions showed that F-1394 reduced the CM+VLDL
(d<1.006) and LDL (1.006<d<1.063) fractions by 54% and 20%,
respectively (Table 2).
As shown in Table 2, the serum TG level was higher in the
diabetic control rats than in the nondiabetic rats
(P<0.10). Also, as shown in Figure 3C, the serum TG
levels reached 1016±298 mg/dL 4 hours after the administration of the
cocktail in the diabetic control rats. The serum TG level from the
diabetic rats that were given F-1394 at a dose of 3 or 10 mg/kg was
reduced by 44% or 24%, respectively; however, there was no statistic
difference in serum TG level among the 3 groups. Also, the reduction
was not in a dose-dependent manner (Figure 3C), unlike serum TC
levels. In contrast, F-1394 at a dose of 30 mg/kg significantly reduced
the serum TG level in the diabetic rats (Table 2, Figure 3C).
The ex vivo ACAT activity in small intestinal mucosa from the normal
rats and the diabetic rats was measured to ensure the effect of F-1394.
As shown in Figure 4, the ACAT activity
in normal rats was 0.93±0.30 pmol · mg
protein-1 · min-1
(P=0.049 versus diabetic control rats), and in diabetic
control rats, it was 9 times higher than this (8.65±3.24 pmol ·
mg protein-1 ·
min-1). In contrast, the activity in the
diabetic F-1394–treated rats was significantly less than that in the
diabetic control rats (1.10±0.39 pmol · mg
protein-1 · min-1,
P=0.053 versus diabetic control rats).
|
Lymphatic Output of Lipids
The lymphatic output of TC or TG and in the presence of F-1394 was
followed for 24 hours after administration of the cocktail via the
gastric tube. As shown in Figure 5A, the
TC output in the diabetic control rats was sharply increased and
reached a peak at 5 hours after administration of the cocktail
(3.58±0.97 mg/h). Then the change in the TC output was gradually
decreased. In contrast to this, the increase in the TC output in the
diabetic rats with F-1394 was more moderate than that in the diabetic
control rats. The TC output in the diabetic rats with F-1394 reached a
plateau at 6 hours after the administration of the cocktail, and then
the plateau was maintained until 10 hours after the administration
(1.4 mg/h). After that, the decline of the TC output behaved as in
diabetic control rats.
|
As shown in Figure 5B, the TG output in the diabetic control
rats was drastically increased and also reached a peak at 5 hours after
administration of the cocktail (101.1±23.5 mg/h), and the change in
the TG output was sequentially decreased. Despite the increase in TG
output, the diabetic rats with F-1394 behaved the same as the diabetic
control rats until 3 hours after the administration; the TG output had
already reached submaximal, and then the steady state was sustained
until 9 hours after the administration, with some variance (36.6±3.3
to 53.6±7.8 mg/h). The decline of the TG output behaved almost the
same as in diabetic control rats.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Although many investigators have reported that severe hyperlipidemia can be induced in STZ-diabetic rats by exogenous fat loading and although they have discussed the mechanisms involved,17 18 19 20 21 22 23 24 serum lipid metabolism in the postprandial state has not been investigated.
In the present study, we performed experiments to determine whether
small intestinal ACAT is activated in STZ-diabetic rats in the
absence of both high fat diet and hyperplasia in the gut. Hyperglycemia
was detectable in rats on the third day after the STZ injection and
beyond, and the body weight and small intestine weight remained fairly
stable in diabetic rats, whereas they increased progressively in normal
rats (Table 1). These results indicated that hyperplasia was not
induced in the gut of diabetic rats fed 30 g of regular chow per
day per rat, at least up to 21 days after the STZ injection (Figure 1). These results indicate that small intestinal ACAT activity
is elevated under diabetic conditions in the absence of both a high fat
diet and hyperplasia in the gut, presumably because it is released from
its normal control by insulin. In fact, Jiao et al20 first
reported that ACAT activity in the gut was elevated in diabetic rats
without a high fat diet and that the enhanced small intestinal ACAT
activity can be suppressed by treatment with insulin. Furthermore,
several investigators21 22 23 24 showed that the enhanced ACAT
activity in the gut was inhibited by ACAT inhibitors,
subsequently resulting in reduced serum TC levels in diabetic rats
loaded with a high fat diet. Maechler and colleagues22 23
demonstrated that an elevation of intestinal ACAT activity could be
observed in diabetic rats only 3 days after STZ injection in the
absence of both a high fat diet and hyperplasia in the gut. Our results
are almost the same as theirs, despite the differences in study design.
Thus, our data suggest that a deficiency of insulin leads to an
addition of small intestinal ACAT activity even in the absence of an
induction of hyperplasia in the gut and hyperphagia. Jiao et
al34 have reported that insulin inhibited not only fatty
acid incorporation into lipids, such as cholesteryl ester (CE), TG, and
PL in cultured Caco-2 cells, which are a human intestinal cell line,
but also microsomal ACAT activity isolated from the cells; they further
suggested that insulin did not affect synthesis of ACAT protein but
some modifications of ACAT protein. However, detailed mechanisms of
insulin on ACAT activity still remain unclear.
In the past several years, molecular biological approaches have given us new information regarding the ACAT molecule itself and its physiological roles and pathogenicity since Chang et al35 first cloned the cDNA encoding the human ACAT enzyme, termed ACAT-1. Subsequently, ACAT-1 cDNA has been cloned in hamsters,36 mice,37 rabbits,38 and rats,39 and ACAT-1 mRNA and/or its product have been found in various tissues, including the small intestine.37 38 39 40 41 However, it has been suggested that the ACAT-1 enzyme is not involved in cholesterol absorption via the gut because ACAT-1 gene disruption did not affect cholesterol absorption in mice.42 Human intestinal ACAT activity was also immunodepleted by only 20% by the anti-human ACAT-1 antibody DM-10, which inhibited ACAT activities by >80% in the liver, adrenal gland, macrophages, and kidney.41 Therefore, it has been suggested that there are isoenzymes of ACAT that catalyze cholesterol absorption. Recently, a new ACAT isoenzyme, named ACAT-2, was cloned in mice,43 monkeys,44 and humans,45 and its mRNA was primarily expressed in the liver and small intestine, unlike ACAT-1. As described in the studies mentioned above, the investigators speculated that ACAT-2 is expected to be responsible for CE secretion from the liver and intestine but not for its deposition. Thus, it could be postulated that ACAT-2 is regulated by insulin and that the ACAT-2 enzyme is activated in diabetic conditions. Further investigations are required to distinguish the regulation of ACATs by insulin.
Previous investigators,20 21 22 23 24 including Maechler and
colleagues,22 23 have not been able to show a correlation
between the postprandial changes in serum lipids and the severe
hyperlipidemia seen in diabetic rats fed a high fat
diet. For this reason, we investigated the postprandial levels of serum
lipids in diabetic rats (in which the rise in small intestinal ACAT
would be expected to be elevated by the use of an oral fat-loading
test). Diabetic rats that had been fasted overnight for 14 days after
the injection of STZ or its vehicle were used for the oral fat-loading
test. The serum TC levels in such diabetic rats increased rapidly after
the oral administration of the high fat cocktail (Figure 2A).
Moreover, the increase in serum TG was greatly enhanced in diabetic
rats (compared with normal rats) (Figure 2B). From these
results, we conclude that PH is induced in STZ-diabetic rats by the
feeding of fat. Also, it is suggested that hyperphagia and hyperplasia
in the gut are not necessarily the predominant mechanisms for induction
of hyperlipidemia in STZ-diabetic rats. These findings
support the findings of Maechler and colleagues.22 23
Whereas the TC levels reached steady state at 6 hours after the
administration of the cocktail, the TC level should be more increased
than that seen in the diabetic rats, as shown in Figure 2A, when
the diabetic rats are continuously administered the cocktail or fed a
high fat diet. Furthermore, our results may suggest that the severe
hyperlipidemia seen in STZ-diabetic rats continually
fed a high fat diet occurs as a result of the abnormal increase in fat
absorption via the gut that occurs repeatedly in the postprandial
state.
We have reported that F-1394 diminished intestinal
cholesterol absorption and subsequently reduced serum TC
levels in nondiabetic animals fed a high fat diet.26 27
Even in the present oral fat-loading test, a single administration
of F-1394, an ACAT inhibitor, to diabetic rats markedly
decreased the serum level of TC, including CM+VLDL and LDL fractions
(Figure 3B and Table 2), the elevated ACAT activity in
the small intestine (Figure 4), and the lymphatic output of
cholesterol (Figure 5A). These results strongly
suggest that PH is attributable to an abnormal increase in small
intestinal ACAT activity and that intestinal ACAT regulates
cholesterol absorption via the gut. Moreover, only a high
dose of F-1394 (30 mg/kg) unexpectedly decreased TG levels (Figure 3C and Table 2) and the lymphatic output of TG (Figure 5B) in this model, whereas F-1394 decreased TC levels in a
dose-dependent manner. Previously, we reported the same observation
that a high dose of F-1394 deceased TG levels in the postprandial state
in normal beagle dogs fed a high fat diet, whereas F-1394 decreased TC
levels in a dose-dependent manner.27 In nondiabetic normal
rats fed a high fat diet, F-1394 also decreased serum TG levels in the
postprandial state (J.K. et al, unpublished data, 1998). From
these findings, it seems that the mechanisms of TG absorption
inhibition by F-1394 via the gut are different from that of
cholesterol absorption, because the potency of F-1394 in
the reduction of TG is not concomitant with that the potency in the
reduction of TC (Figure 3). Although the exact relation between
TG absorption via the gut and intestinal ACAT activity still remains
unclear, it could be that production of CM in the gut is
controlled by intestinal ACAT in both the normal and the diabetic rats.
Recently, a factor that is predominant in lipoprotein
production was found in the liver, namely, microsomal TG
transfer protein (MTP).46 47 This protein has also been
found in the small intestine,48 and CE, which is a
product of ACAT, and TG have been found to be essential substrates
for MTP.46 Thus, the
hypotriglyceridemic effect of F-1394 may cause a
reduction in CM synthesis in the gut that is secondary to a reduction
in MTP activity caused by lack of one of the substrates for MTP (such
as CE). Recently, Martins et al49 have shown that an ACAT
inhibitor, CL277,082, decreased the lymphatic output of
apoB48 and TG, and they have discussed also that synthesis of apoB48
and CM in the intestine may be regulated by the availability of CE.
Alternatively, it is suggested that F-1394 may reduce TG absorption as
a result of a direct inhibition of MTP activity in the intestine. In
fact, a preliminary study in our laboratory has revealed that
microsomal lipid transfer activity in rat small intestinal mucosa was
affected by high concentrations of F-1394 (>1 mmol/L) in vitro
(J.K. et al, unpublished data, 1998), and an incorporation of free
fatty acid into TG was not attenuated by F-1394 in cultured Caco-2
cells (J.K. et al, unpublished data, 1994). The distribution study that
used radioactive F-1394 has shown that rat small intestine contains a
sufficient mass of F-1394 to inhibit such an activity after the oral
administration (Fujirebio, unpublished data, 1994). Moreover, a lack of
MTP activity is significantly involved in
abetalipoproteinemia,47 50 a rare autosomal recessive
disease characterized by the absence of VLDL and LDL from plasma, and
fat malabsorption.51 Therefore, a partial inhibition of
intestinal MTP activity by compounds may cause an inhibition of fat
absorption via the gut.
Presumably, both mechanisms may be involved in the attenuation of TG absorption. However, at present, these are only speculations, and further studies will be necessary to clarify the actual mechanism.
We have previously demonstrated that F-1394 interferes with
cholesterol absorption via the gut as a result of its
inhibition of small intestinal ACAT activity in rats fed a high
cholesterol diet.26 In the present study,
we found that F-1394 decreased serum TC levels, mainly CM+VLDL (Table 2), and that it also inhibited small intestinal ACAT activity ex
vivo (Figure 4). In another study in STZ-diabetic rats, no delay
in the plasma clearance or liver uptake of CM or CM remnants was
observed.52 These data strongly suggest that the
hypocholesterolemic action of F-1394 in diabetic rats
results mainly from a suppression of cholesterol absorption
via the gut. This is in accord with the results
of our previous studies26 28 and with those of other
studies that used the ACAT inhibitor.21 22 23 24 49
Also, F-1394 slightly reduced TC levels in the LDL fraction (Table 2). This result suggests that this compound may affect VLDL
secretion from the liver in this model as well. Indeed, the
hypocholesterolemic effect by ACAT
inhibitors caused by the reduction of VLDL
production in the liver that resulted from hepatic ACAT
inhibition is expected,53 54 55 56 and we have determined that
F-1394 prevents VLDL secretion in hyperlipidemic rats
induced by Triton WR-1339.57 Another possibility could be
that a stimulation of VLDL production by excess plasma
concentrations of intestine-derived lipoproteins are diminished by an
attenuation of cholesterol absorption by F-1394 in diabetic
rats.
Recently, abnormalities of the metabolism of serum lipoproteins,3 5 9 TG,4 and TC6 7 8 in the postprandial state have been reported in diabetic patients. It has been demonstrated that higher cholesterol absorption efficiency has been observed in diabetic patients with CHD but not in patients without CHD.16 That study16 suggests that the abnormal increase of cholesterol absorption in the postprandial state greatly contributes to CHD in diabetic patients. Similarly, increased postprandial triglyceridemia is strongly associated with a constellation of potentially atherogenic and thrombogenic lipoprotein changes. Thus, PH is recognized as a significant risk factor for CHD. The results of the present study suggest that an abnormal increase in intestinal ACAT activity can induce PH in rats. Consequently, a treatment causing cholesterol malabsorption by F-1394, an ACAT inhibitor, could be beneficial in these patients.
In summary, we established a PH model in STZ-diabetic rats by the single oral administration of a high fat cocktail. The PH was apparently induced by the abnormal increase in intestinal ACAT activity that occurs in STZ-diabetic rats. Indeed, an ACAT inhibitor, F-1394, improved the PH apparently as a result of its inhibition of intestinal ACAT activity.
Received May 31, 1999; accepted August 19, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in Framingham population: sixteen year follow-up study. Diabetes. 1974;23:105–111.[Medline] [Order article via Infotrieve]
2. American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care.. 1989;12:573–579.[Medline] [Order article via Infotrieve]
3. Ooi TC, Simo IE, Yakichuk JA. Delayed clearance of postprandial chylomicrons and their remnants in the hypoalphalipoproteinemia and mild hypertriglyceridemia syndrome. Arterioscler Thromb.. 1992;12:1184–1190.[Abstract]
4.
Lewis GF, O’Meara NM, Soltys PA, Blackman JD, Iverius
PH, Pugh WL, Getz GS, Polonsky KS. Fasting
hypertriglyceridemia in
noninsulin-dependent diabetes mellitus is an important predictor of
postprandial lipid and lipoprotein abnormalities. J Clin
Endocrinol Metab.. 1991;72:934–944.
5. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol.. 1994;5:102–109.[Medline] [Order article via Infotrieve]
6. Cavallero E, Dachet C, Neufcour D, Wirquin E, Mathe D, Jacotot B. Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels. Metabolism. 1994;43:270–278.[Medline] [Order article via Infotrieve]
7. Curtin A, Deegan P, Owens D, Collins P, Johnson A, Tomkin GH. Alterations in apolipoprotein B-48 in the postprandial state in NIDDM. Diabetologia. 1994;37:1259–1264.[Medline] [Order article via Infotrieve]
8. Gylling H, Miettinen TA. The effect of cholesterol absorption inhibition on low density lipoprotein cholesterol level. Atherosclerosis. 1995;117:305–308.[Medline] [Order article via Infotrieve]
9. Coppack SW. Postprandial lipoproteins in non-insulin-dependent diabetes mellitus. Diabet Med.. 1997;14:S67–S74.
10. Cohn JS. Postprandial lipemia: emerging evidence for atherogenicity of remnant lipoproteins. Can J Cardiol.. 1998;14:18B–27B.
11. Ebenbichler CF, Kirchmair R, Egger C, Patsch JR. Postprandial state and atherosclerosis. Curr Opin Lipidol.. 1995;6:286–290.[Medline] [Order article via Infotrieve]
12. Floren CH, Chait A. Uptake of chylomicron remnants by the native LDL receptor in human monocyte-derived macrophages. Biochim Biophys Acta.. 1981;665:608–611.[Medline] [Order article via Infotrieve]
13.
Van Lenten BJ, Fogelman AM, Jackson RL, Shapiro S,
Haberland ME, Edwards PA. Receptor-mediated uptake of remnant
lipoproteins by cholesterol-loaded human
monocyte-macrophages. J Biol Chem.. 1985;260:8783–8788.
14. Davignon J, Cohn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis. 1996;124:S57–S64.
15. Krauss RM. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med.. 1998;105:58S–62S.[Medline] [Order article via Infotrieve]
16. Gylling H, Miettinen TA. Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease. Atherosclerosis. 1996;126:325–332.[Medline] [Order article via Infotrieve]
17. Arbeeny CM, Edelstein D, Freedman SR, Eder HA. Serum lipoproteins of diabetic rats fed a high cholesterol diet. Diabetes. 1980;29:774–777.[Abstract]
18. Colca JR, Dailey CF, Palazuk BJ, Hillman RM, Dinh DM, Melchior GW, Spilman CH. Pioglitazone hydrochloride inhibits cholesterol absorption and lowers plasma cholesterol concentrations in cholesterol-fed rats. Diabetes. 1991;40:1669–1674.[Abstract]
19. Young NL, Lopez DR, McNamara DJ, Benavides G. Evaluation of the contribution of dietary cholesterol to hypercholesterolemia in diabetic rats and of sitosterol as a recovery standard for cholesterol absorption. J Lipid Res.. 1985;26:62–69.[Abstract]
20. Jiao S, Matsuzawa Y, Matsubara K, Kihara S, Nakamura T, Tokunaga K, Kubo M, Tarui S. Increased activity of intestinal acyl-CoA:cholesterol acyltransferase in rats with streptozotocin-induced diabetes and restoration by insulin supplementation. Diabetes. 1988;37:342–346.[Abstract]
21.
Matsubara K, Matsuzawa Y, Jiao S, Kihara S, Takama T,
Nakamura T, Tokunaga K, Kubo M, Tarui S.
Cholesterol-lowering effect of
N-(
-methylbenzyl)linoleamide (melinamide) in
cholesterol-fed diabetic rats.
Atherosclerosis. 1988;72:199–204.[Medline]
[Order article via Infotrieve]
22. Maechler P, Wollheim CB, Bentzen CL, Niesor E. Role of the intestinal acyl-CoA:cholesterol acyltransferase activity in the hyperresponse of diabetic rats to dietary cholesterol. J Lipid Res.. 1992;33:1475–1484.[Abstract]
23. Maechler P, Wollheim CB, Bentzen CL, Niesor E. Importance of exogenous cholesterol in diabetic rats: effects of treatment with insulin or with an acyl-CoA:cholesterol acyltransferase inhibitor. Ann Nutr Metab.. 1993;37:199–209.[Medline] [Order article via Infotrieve]
24. Sakuma Y, Hagihara H, Nagayoshi A, Ohne K, Mutoh S, Ito Y, Nakahara K, Notsu Y, Okuhara M. Effect of FR145237, an acyl-CoA:cholesterol acyltransferase inhibitor, on diet-induced hypercholesterolemia in diabetic rats. Life Sci.. 1997;60:351–356.[Medline] [Order article via Infotrieve]
25. Kusunoki J, Aragane K, Yamaura T, Ohnishi H. Studies on acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory effects and enzyme selectivity of F-1394, a pantothenic acid derivative. Jpn J Pharmacol.. 1995;67:195–203.[Medline] [Order article via Infotrieve]
26. Kusunoki J, Aragane K, Kitamine T, Higashinakagawa S, Kase N, Yamaura T, Ohnishi H. Hypocholesterolemic action and prevention of cholesterol absorption via the gut by F-1394, a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, in cholesterol diet-fed rats. Jpn J Pharmacol.. 1995;69:53–60.[Medline] [Order article via Infotrieve]
27. Kusunoki J, Aragane K, Kitamine T, Yamaura T, Ohnishi H. Hypolipidemic action of F-1394, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, in high-fat diet fed beagle dogs. Yakugaku Zasshi. 1997;117:233–241.[Medline] [Order article via Infotrieve]
28. Kusunoki J, Aragane K, Kitamine T, Yamaura T, Ohnishi H. Effect of F-1394, a potent and selective inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), on esterification of cholesterol and basolateral secretion of cholesteryl ester in Caco-2 cells. Nippon Yakurigaku Zasshi.. 1997;110:357–365.[Medline] [Order article via Infotrieve]
29. Heider JG, Pickens CE, Kelly LA. Role of acyl CoA:cholesterol acyltransferase in cholesterol absorption and its inhibition by 57–118 in the rabbit. J Lipid Res.. 1983;24:1127–1134.[Abstract]
30. Bollman JL, Cain JC, Grindlay JH. Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J Lab Clin Med.. 1948;33:1349–1352.[Medline] [Order article via Infotrieve]
31. Osada K, Sasaki E, Sugano M. Lymphatic absorption of oxidized cholesterol in rats. Lipids.. 1994;29:555–559.[Medline] [Order article via Infotrieve]
32. Ikeda I, Tanaka K, Sugano M, Vahouny GV, Gallo LL. Inhibition of cholesterol absorption in rats by plant sterols. J Lipid Res.. 1988;29:1573–1582.
33. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest.. 1955;34:1345–1353.
34. Jiao S, Moberly JB, Cole TG, Schonfeld G. Decreased activity of acyl-CoA:cholesterol acyltransferase by insulin in human intestinal cell line Caco-2. Diabetes. 1989;38:604–609.[Abstract]
35.
Chang CCY, Huh HY, Cadigan KM, Chang TY. Molecular
cloning and functional expression of human acyl-coenzyme
A:cholesterol acyltransferase cDNA in mutant Chinese
hamster ovary cells. J Biol Chem.. 1993;268:20747–20775.
36.
Cao G, Goldstein JL, Brown MS. Complementation of
mutation in acyl-CoA:cholesterol acyltransferase (ACAT)
fails to restore sterol regulation in ACAT-defective
sterol-resistant hamster cells. J Biol Chem. 1996;271:14642–14648.
37.
Uelmen PJ, Oka K, Sullivan M, Chang CCY, Chang TY, Chan
L. Tissue-specific expression and cholesterol regulation of
acylcoenzyme A:cholesterol acyltransferase (ACAT) in mice.
J Biol Chem. 1995;270:26192–26201.
38. Pape ME, Schultz PA, Rea TJ, DeMattos RB, Kieft K, Bisgaier CL, Newton RS, Krause BR. Tissue specific changes in acyl-CoA:cholesterol acyltransferase (ACAT) mRNA levels in rabbits. J Lipid Res. 1995;36:823–838.[Abstract]
39. Matsuda H, Hakamata H, Kawasaki T, Sakashita N, Miyazaki A, Takahashi K, Shichiri M, Horiuchi S. Molecular cloning, functional expression and tissue distribution of rat acyl-CoA:cholesterol acyltransferase. Biochim Biophys Acta. 1998;1391:193–203.[Medline] [Order article via Infotrieve]
40.
Chang CCY, Chen J, Thomas MA, Cheng D, Del Priore
VA, Newton RS, Pape ME, Chang TY. Regulation and immunolocalization of
acyl-coenzyme A:cholesterol acyltransferase in mammalian
cells as studied with specific antibodies. J Biol Chem. 1995;270:29532–29540.
41.
Lee O, Chang CCY, Lee W, Chang TY. Immunodepletion
experiments suggest that acyl-coenzyme A:cholesterol
acyltransferase-1 (ACAT-1) protein plays a major catalytic role in
adult human liver, adrenal gland, macrophages and kidney, but
not in intestines. J Lipid Res. 1998;39:1722–1727.
42.
Meiner VL, Cases S, Myers HM, Sande ER, Bellosta S,
Schambelan M, Pitas RE, McGuire J, Herz J, Farese RV Jr. Disruption of
the acyl-CoA:cholesterol acyltransferase gene in mice:
evidence suggesting multiple cholesterol esterification
enzymes in mammals. Proc Natl Acad Sci U S A. 1996;93:14041–14046.
43.
Cases S, Novak S, Zheng YW, Myers HM, Lear SR, Sande E,
Welch CB, Lusis AJ, Spencer TA, Krause BR, Erickson SK, Farese RV Jr.
ACAT-2, a second mammalian acyl-CoA:cholesterol
acyltransferase. J Biol Chem. 1998;273:26755–26764.
44.
Anderson RA, Joyce C, Davis M, Reagan JW, Clark M,
Shelness GS, Rudel LL. Identification of a form of
acyl-CoA:cholesterol acyltransferase specific to liver and
intestine in nonhuman primates. J Biol Chem. 1998;273:26747–26754.
45.
Oelkers P, Behari A, Cromley D, Billheimer JT, Sturley
SL. Characterization of two genes encoding acyl coenzyme
A:cholesterol acyltransferase-related enzymes. J
Biol Chem. 1998;273:26765–26771.
46. Wetterau JR, Zilversmit DB. Purification and characterization of microsomal triglyceride and cholesteryl ester transfer protein from bovine liver microsomes. Chem Phys Lipids. 1985;38:205–222.[Medline] [Order article via Infotrieve]
47. Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, Gil CM, Turck CW, Bouma ME, Rader DJ, Aggerbeck LP, Gregg RE, Gordon DA, Wetterau JR. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature. 1993;365:65–69.[Medline] [Order article via Infotrieve]
48. Wetterau JR, Zilversmit DB. Localization of intracellular triacylglycerol and cholesteryl ester transfer activity in rat tissues. Biochim Biophys Acta. 1986;875:610–617.[Medline] [Order article via Infotrieve]
49.
Martins IJ, Mortimer BC, Redgrave TG. Effect of the
ACAT inhibitor CL 277,082 on apolipoprotein B48 transport
in mesenteric lymph and on plasma clearance of chylomicrons and
remnants. Arterioscler Thromb Vasc Biol.. 1997;17:211–216.
50.
Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck
A, Hermier M, Schmitz J, Gay G, Rader DJ, Gregg RE. Absence of
microsomal triglyceride transfer protein in individuals
with abetalipoproteinemia. Science.. 1992;258:999–1001.
51. Kane JP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing B apolipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York, NY: McGraw-Hill; 1989:1139–1164.
52. Staprans I, Pan XM, Rapp JH, Feingold KR. Chylomicron and chylomicron remnant metabolism in STZ-induced diabetic rats. Diabetes. 1992;41:325–333.[Abstract]
53. Sliskovic DR, White AD. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol Sci1991;12:194–199.
54. Tanaka M, Jingami H, Otani H, Cho M, Ueda Y, Arai H, Nagano Y, Doi T, Yokode M, Kita T. Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes. J BiolChem.. 1993;268:12713–12718.
55.
Krause BR, Pape ME, Kieft K, Auerbach B, Bisgaier CL,
Homan R, Newton RS. ACAT inhibition decreases LDL
cholesterol in rabbits fed a cholesterol-free
diet: marked changes in LDL cholesterol without changes in
LDL receptor mRNA abundance. Arterioscler Thromb.. 1994;14:598–604.
56.
Huff MW, Telford DE, Barrett PHR, Billheimer JT,
Gillies PJ. Inhibition of hepatic ACAT decreases apoB secretion in
miniature pigs fed a cholesterol-free diet.
Arterioscler Thromb.. 1994;14:1498–1508.
57. Aragane K, Kusunoki J, Kitamine T, Yamaura T, Ohnishi H. Effects of F-1394, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on ACAT activity in HepG2 cells and on hepatic secretion of lipids in Triton WR-1339-induced hyperlipidemic rats: possible role of hepatic ACAT in very low density lipoprotein secretion. Jpn J Pharmacol.. 1998;76:309–312.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  M. Hori, M. Satoh, K. Furukawa, Y.-i. Sakamoto, H. Hakamata, Y. Komohara, M. Takeya, Y. Sasaki, A. Miyazaki, and S. Horiuchi Acyl-Coenzyme A:Cholesterol Acyltransferase-2 (ACAT-2) Is Responsible for Elevated Intestinal ACAT Activity in Diabetic Rats Arterioscler Thromb Vasc Biol, September 1, 2004; 24(9): 1689 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kusunoki, D. K. Hansoty, K. Aragane, J. T. Fallon, J. J. Badimon, and E. A. Fisher Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice Circulation, May 29, 2001; 103(21): 2604 - 2609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Aragane, K. Fujinami, K. Kojima, and J. Kusunoki ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits J. Lipid Res., April 1, 2001; 42(4): 480 - 488. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||